AMENDMENTS TO THE CLAIMS

1 to 13. (Canceled).

14. (Currently Amended) A pharmaceutical kit comprising 4-hydroxyisoleucine and one or more additional antidiabetic agents selected from the following types of antidiabetic agents: biguanides, sulfonylurea drugs, glinides, insulin-sensitizing agents, glucagon-like peptide 1 receptor agonists, agents that slow carbohydrate absorption, glucagon antagonists, glucokinase activators, imidazolines, glycogen phosphorylase inhibitors, oxadiazolidinediones, dipeptidyl peptidase-IV inhibitors, protein tyrosine phosphatase inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis or glycogenolysis, glucose uptake modulators, glycogen synthase kinase-3 inhibitors, antihyperlipidemic agents, antilipidemic agents, peroxisome proliferator-activated receptor agonists, retinoid X receptor agonists, and antihypertensive agents.

15. (Original) The pharmaceutical kit of claim 14, wherein the 4-hydroxyisoleucine is the 2S,3R,4S isomer of 4-hydroxyisoleucine.

16 and 17. (Canceled).

18. (Currently Amended) The pharmaceutical kit of claim ~~17~~14, wherein the ~~biguanide~~ additional antidiabetic agent is metformin.

19 to 22. (Canceled).

23. (Currently Amended) The pharmaceutical kit of claim ~~22~~14, wherein the ~~thiazolidinedione~~ additional antidiabetic agent is rosiglitazone maleate or pioglitazone.

24. (Canceled).

25. (Currently Amended) The pharmaceutical kit of claim ~~24~~14, wherein the ~~glucagon-like peptide 1 receptor agonist~~ additional antidiabetic agent is Exenatide®.

26. (Currently Amended) The pharmaceutical kit of ~~any one of claims~~ claim 14 ~~to 16~~, wherein the hydroxylated amino acid and the additional antidiabetic agent are formulated into a single composition.

27. (Original) The pharmaceutical kit of claim 26, wherein the single composition is a tablet or a capsule.

28. (Currently Amended) A pharmaceutical composition comprising 4-hydroxyisoleucine, one or more additional antidiabetic agents and a pharmaceutically acceptable excipient, wherein said additional antidiabetic agent(s) is selected from the following types of antidiabetic agents: biguanides, sulfonylurea drugs, glinides, insulin-sensitizing agents, glucagon-like peptide 1 receptor agonists, agents that slow carbohydrate absorption, glucagon antagonists, glucokinase activators, imidazolines, glycogen phosphorylase inhibitors, oxadiazolidinediones, dipeptidyl peptidase-IV inhibitors, protein tyrosine phosphatase inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis or glycogenolysis, glucose uptake modulators, glycogen synthase kinase-3 inhibitors, antihyperlipidemic agents, antilipidemic agents, peroxisome proliferator-activated receptor agonists, retinoid X receptor agonists, and antihypertensive agents.

29. (Currently Amended) ~~Use of a pharmaceutical kit according to any one of claims 14 to 27, or of a~~ The pharmaceutical composition according to claim 28, for treating diabetes in a patient.

30. (Original) A method of treating diabetes in a patient, the method comprising administering to the patient 4-hydroxyisoleucine and one or more additional antidiabetic agents selected from the following types of antidiabetic agents: biguanides, sulfonylurea drugs, glinides,

insulin-sensitizing agents, glucagon-like peptide 1 receptor agonists, agents that slow carbohydrate absorption, glucagon antagonists, glucokinase activators, imidazolines, glycogen phosphorylase inhibitors, oxadiazolidinediones, dipeptidyl peptidase-IV inhibitors, protein tyrosine phosphatase inhibitors, inhibitors of hepatic enzymes involved in stimulation of gluconeogenesis or glycogenolysis, glucose uptake modulators, glycogen synthase kinase-3 inhibitors, antihyperlipidemic agents, antilipidemic agents, peroxisome proliferator-activated receptor agonists, retinoid X receptor agonists, and antihypertensive agents.

31. (Original) The method of claim 30, wherein the 4-hydroxyisoleucine is the 2S,3R,4S isomer of 4-hydroxyisoleucine.

32. (Original) The method of claim 30, further comprising administering insulin to the patient.

33. (Original) The method of claim 30, wherein the additional antidiabetic agent is a biguanide.

34. (Original) The method of claim 33, wherein the biguanide is metformin.

35. (Original) The method of claim 30, wherein the additional antidiabetic agent is a sulfonylurea drug.

36. (Original) The method of claim 30, wherein the additional antidiabetic agent is a glinide.

37. (Original) The method of claim 30, wherein the additional antidiabetic agent is an insulin-sensitizing agent.

38. (Original) The method of claim 37, wherein the insulin-sensitizing agent is a thiazolidinedione.

39. (Original) The method of claim 38, wherein the thiazolidinedione is rosiglitazone maleate or pioglitazone.

40. (Original) The method of claim 30, wherein the additional antidiabetic agent is a glucagon-like peptide 1 receptor agonist.

41. (Original) The method of claim 40, wherein the glucagon-like peptide 1 receptor agonist is Exenatide®.

42. (Original) The method of claim 30, wherein the diabetes is type 2 diabetes.

43. (Original) The method of claim 30, wherein the hydroxylated amino acid is administered to the patient at or about the same time as the additional antidiabetic agent.